Latest news with #Ayvakyt
Yahoo
7 days ago
- Business
- Yahoo
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion. Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion. A doctor examining a patient's samples in a modern hospital setting. In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The upfront offer price represents a 27-percent premium over Blueprint's closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025. The purchase will also include the latter's rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM). READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
7 days ago
- Business
- Yahoo
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion. Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion. A doctor examining a patient's samples in a modern hospital setting. In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The upfront offer price represents a 27-percent premium over Blueprint's closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025. The purchase will also include the latter's rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM). READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
03-06-2025
- Business
- Yahoo
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading. The deal expands Sanofi's immunology pipeline and access to drugs to treat systemic mastocytosis (SM), a rare immunological disease. Sanofi CEO Paul Hudson said that the French company "still retains a sizeable capacity for further acquisitions."French drugmaker Sanofi (SNY) said Monday it has agreed to acquire Blueprint Medicines (BPMC) for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in in intraday trading. The deal expands Sanofi's immunology pipeline and access to drugs to treat systemic mastocytosis (SM), a rare immunological disease, and "other KIT-driven diseases," the company said. Sanofi also noted that the acquisition would give it access to rare immunology disease medicine avapritinib, marketed as Ayvakit or Ayvakyt, which has been approved in the U.S. and the European Union (EU). "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios," Sanofi CEO Paul Hudson said, adding that the French company "still retains a sizeable capacity for further acquisitions." Under the terms of the Blueprint transaction, Sanofi will pay $129.00 per share in cash or $9.1 billion as well as potential milestone payments. The deal is the latest by the French pharma giant, which last month agreed to buy Alzheimer's disease drug developer Vigil Neuroscience (VIGL). Sanofi shares were down slightly Monday but are up 2% year-to-date through Friday. Blueprint shares are gaining 26% in intraday trading and have risen 16% entering Monday. UPDATE—June 2, 2025: This article has been updated to include refreshed share prices. Read the original article on Investopedia
Yahoo
02-06-2025
- Business
- Yahoo
Sanofi to expand immunology offerings with Blueprint Medicines
Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline with rare disease treatments. The acquisition includes Ayvakit/Ayvakyt (avapritinib), a rare immunology disease medicine approved in the US and European Union (EU), and an early-stage immunology pipeline. Ayvakit/Ayvakyt is the only medicine for treating advanced and indolent systemic mastocytosis (ASM & ISM), a condition marked by abnormal mast cell accumulation. The acquisition also adds elenestinib, a medicine for systemic mastocytosis, and an oral wild-type KIT inhibitor BLU-808, for a wide range of immunological diseases. Sanofi has committed to pay $129.00 per share in cash at close. Blueprint shareholders will obtain a non-tradeable contingent value right (CVR), which could lead to further payments based on future milestones for BLU-808. The total value, inclusive of potential CVR payments, could reach $9.5bn. The offer price indicates a 27% premium on Blueprint's closing price as of 30 May 2025, and a 34% premium over the 30-day volume-weighted average price (VWAP). Upon completion of the tender offer, a Sanofi subsidiary will merge with and into Blueprint, and non-tendered shares will be converted into the right to receive the same $129.00 per share in cash plus one CVR. Sanofi plans to finance this transaction using existing cash reserves and proceeds from new debt, with no financing condition attached to the tender offer. Sanofi CEO Paul Hudson stated: "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company. 'This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, to bring relevant and differentiated medicines to patients and to secure attractive returns to our shareholders. 'It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions.' Sanofi recently agreed to acquire Vigil Neuroscience for $470m, almost a year after investing an initial $40m in the company. "Sanofi to expand immunology offerings with Blueprint Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Times
02-06-2025
- Business
- Business Times
Sanofi to buy immunology biotech Blueprint for US$9.1 billion
[PARIS] Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay US$129 per share in cash for the US biotech, it said in a statement. That represents a 27 per cent premium to Blueprint's closing price on May 30. The pharmaceutical firm has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to US$1.9 billion. Blueprint brings a pipeline of experimental immunology treatments and one medicine already on sale for a rare condition known as systemic mastocytosis. 'Sanofi still retains a sizable capacity for further acquisitions,' said chief executive officer Paul Hudson. Pharmaceutical companies have shied away from larger deals in recent years, with the biggest so far in 2025 being Johnson & Johnson's acquisition of Intra-Cellular Therapies for US$14.6 billion. The transaction announced on Monday (Jun 2) is the largest for Sanofi since it bought Bioverativ, a spinoff from biotech giant Biogen, in 2018. It includes a contingent value right linked to the performance of one of Blueprint's experimental drugs. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'We see synergies with Sanofi's existing rare-disease footprint, but expect investors to question valuation and confidence in the remaining internal R&D offering,' Sarita Kapila and analyst colleagues at Morgan Stanley wrote in a note. Sanofi shares fell 1 per cent in Paris trading. The stock has dropped about 7.5 per cent so far this year, under-performing European rivals such as GSK and Novartis AG. Blueprint surged 26 per cent in trading before US exchanges opened. Hudson shocked investors in 2023 when his research and development spending plan triggered a profit warning and led to a stock sell-off that wiped out around US$25 billion in market value. Since then, Sanofi has successfully separated its consumer-health division and has worked to prove that the drugmaker's research unit, led by former venture capital hotshot Houman Ashrafian, can continue to produce blockbusters. Potential blockbuster Blueprint markets the drug Ayvakit in the US – known as Ayvakyt in Europe – for systemic mastocytosis, where an abnormal buildup of immune cells can cause symptoms such as hives, abdominal pain, bone pain and anemia. The treatment is projected to bring in US$2 billion in annual revenue by 2030. The company has a medicine called elenestinib in development for the same ailment and another in mid-stage trials called BLU-808 for mast-cell disorders, including chronic urticaria where patients have regular itchy and sometimes painful hives. Blueprint also has an 'established presence' among specialist doctors, according to Sanofi. The acquisition marks the culmination of a successful pivot by Blueprint, which was founded in 2008 and listed in 2015 with a focus on cancer therapies. After the dissolution of a partnership with Roche Holding forced it to withdraw an approved cancer drug from certain markets, it dialled back its efforts in cancer and doubled down on immunology. Blueprint shareholders will also receive one non-tradeable contingent value right, which will pay the holder US$2 and US$4 per right for future development and regulatory milestones for BLU-808, which has the potential to treat a range of diseases. The transaction implies an equity value of US$9.1 billion. Including the potential CVR payments, the deal amounts to about US$9.5 billion on a fully diluted basis. Sanofi expects to complete the acquisition in the third quarter and said the deal will not have a significant impact on its financial guidance for 2025. BLOOMBERG
